DDInter172 DDInter1965
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different
Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. Although it has been nasally administered for treating the common cold, this route of administration has been associated with some cases of anosmia , , , . Studies show that zinc may be better absorbed in humans in the gluconate form , , however, results from other studies may vary.[A27280, L2082] Interestingly, zinc supplementation has become a critical intervention for treating diarrheal episodes in children. Studies suggest that administration of zinc along with new low osmolarity oral rehydration solutions/salts (oral rehydration solution), may reduce both the duration and severity of diarrheal episodes for up to 12 weeks . More information about Zinc (in its natural form) is available at .
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mycophenolic acid
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Satralizumab
Zinc gluconate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gatifloxacin
Zinc gluconate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baloxavir marboxil
Zinc gluconate {u} may lead to a major life threatening interaction when taken with {v} Raltegravir
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Baloxavir marboxil
Zinc gluconate may lead to a major life threatening interaction when taken with Raltegravir